홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Hydrochloric Acid → 8-fluoro-5-[(2-(methyloxy)-4-{4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl}phenyl)amino]-3-[(4-methylphenyl)sulfonyl]pyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-7(3H)-one

HRID 1014442
인쇄

반응식

HRID 1014442 반응식
Cl.[CH3:2][O:3][C:4]1[CH:10]=[C:9]([N:11]2[CH2:16][CH2:15][CH:14]([N:17]3[CH2:22][CH2:21][N:20]([S:23]([CH3:26])(=[O:25])=[O:24])[CH2:19][CH2:18]3)[CH2:13][CH2:12]2)[CH:8]=[CH:7][C:5]=1[NH2:6].Cl[C:28]1[N:29]=[C:30]([NH:47][C:48]2[CH:56]=[CH:55][CH:54]=[C:53]([F:57])[C:49]=2[C:50](N)=[O:51])[C:31]2[CH:36]=[CH:35][N:34]([S:37]([C:40]3[CH:45]=[CH:44][C:43]([CH3:46])=[CH:42][CH:41]=3)(=[O:39])=[O:38])[C:32]=2[N:33]=1.Cl.O1CCOCC1.C([O-])(O)=O.[Na+]>C(Cl)Cl>[F:57][C:53]1[CH:54]=[CH:55][CH:56]=[C:48]2[C:49]=1[C:50](=[O:51])[N:29]1[C:28]([NH:6][C:5]3[CH:7]=[CH:8][C:9]([N:11]4[CH2:16][CH2:15][CH:14]([N:17]5[CH2:18][CH2:19][N:20]([S:23]([CH3:26])(=[O:25])=[O:24])[CH2:21][CH2:22]5)[CH2:13][CH2:12]4)=[CH:10][C:4]=3[O:3][CH3:2])=[N:33][C:32]3[N:34]([S:37]([C:40]4[CH:41]=[CH:42][C:43]([CH3:46])=[CH:44][CH:45]=4)(=[O:38])=[O:39])[CH:35]=[CH:36][C:31]=3[C:30]1=[N:47]2
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

7

반응물 5

HCID 313Hydrochloric AcidHCID 312751,4-DioxaneHCID 516892Sodium BicarbonateHCID 673170002-(Methyloxy)-4-{4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl}aniline hydrochlorideHCID 866441882-({2-chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)-6-fluorobenzamide

생성물 1

HCID 59441947
8-fluoro-5-[(2-(methyloxy)-4-{4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl}phenyl)amino]-3-[(4-methylphenyl)sulfonyl]pyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-7(3H)-one
수율 89.1%

시약·촉매·용매 1

HCID 6344Dichloromethane용매

실험 절차

A solution of 2-(methyloxy)-4-{4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl}aniline hydrochloride (3 g, 7.41 mmol) and 2-({2-chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)-6-fluorobenzamide (3 g, 6.52 mmol) in trifluroroethanol (200 mL) and HCl in dioxane (14.16 ml, 56.6 mmol) and KI (300 mg, 1.807 mmol) was stirred at 90° C. in a 300 mL pressure vessel behind a blast shield for 15 hours. After cooling to rt, the solution was neutralized with aqueous NaHCO3 (400 mL), the black suspension was added to CH2Cl2 (500 mL), and the layers separated. Addition of brine (200 mL) helped to separate the organic and aqueous layers. The organic layers were concentrated under reduced pressure and then suspended in CH2Cl2 (20 mL) and Et2O (150 mL). The solid was filtered to obtain 8-fluoro-5-[(2-(methyloxy)-4-{4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl}phenyl)amino]-3-[(4-methylphenyl)sulfonyl]pyrrolo[2′,3′:4,5]pyrimido[6,1-b]quinazolin-7(3H)-one as brown powder (4.5 g, 5.81 mmol, 89% yield). This material was used without further purification. ESIMS (M+H)+=775.32 (100%).

후처리

  1. customthe layers separated
  2. additionAddition of brine (200 mL)
  3. customto separate the organic and aqueous layers
  4. concentrationThe organic layers were concentrated under reduced pressure
  5. filtrationThe solid was filtered

출처 및 근거

ORD 기록
ord-9978f92389db4ca2914063509864345c
출처 데이터셋
uspto-grants-2011_07
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US07981903B2

반응 노트

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트